Part II: Milestones in personalised medicine-trastuzumab

The Lancet Oncology

Volumn 9, Issue 7, 2008, Pages 698-

  Gelmon, Karen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PERTUZUMAB; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; MONOTHERAPY; NOTE; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HISTORY, 20TH CENTURY; HUMANS;

EID: 45849128985     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70177-3     Document Type: Note

References (5)

1. Slamon D., Godolphin W., Jones L., et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
2. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9 (1989) 1165-1172
3. Musolino A., Naldi A., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab based therapy in patients with HER2/neu positive metastatic breast cancer. J Clin Oncol 26 (2008) 1789-1796
4. Gelmon K., Fumoleau P., Verma S., et al. Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2 positive metastatic breast cancer who had progressed during trastuzumab therapy. Proc Am Soc Clin Oncol 26 (2008) (abstr 1026).
5. Beeram M., Burris H., Modi S., et al. A phase I study of trastuzumab-DM1 a first in class Her2 antibody drug conjugate in patients with advanced HER2+ breast cancer. Proc Am Soc Clin Oncol 26 (2008) (abstr 1028).